Clinical trial · Observational
Chemotherapy in Treating Patients With Lung Cancer
First-line Treatment of Non-Small Cell Lung Cancer Under Routine Conditions: Observational Study on Overall Survival
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study was planned, with the primary objective to observe patient survival following first-line treatment of patients of Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) with different platinum-based doublets under routine disease management conditions. Further secondary objectives of this study are to provide insights to what extent histologic subtyping and the use of additional prognostic or predictive biomarkers are currently considered for differential therapeutic decisions under routine conditions. All of these data are critical to evaluate the factors for differential therapeutic decisions and their effect on patient outcomes in a real life setting, and they can only be obtained through observational research.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Any platinum-based doublet chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- pemetrexed + platinum
- description
- Patients with pemetrexed + platinum doublet, with or without additional targeted agents
- interventionNames
- Drug: Any platinum-based doublet chemotherapy
- label
- gemcitabine + platinum
- description
- Patients with gemcitabine + platinum doublet, with or without additional targeted agents
- interventionNames
- Drug: Any platinum-based doublet chemotherapy
- label
- taxanes + platinum
- description
- Patients with taxanes + platinum doublet, with or without additional targeted agents
- interventionNames
- Drug: Any platinum-based doublet chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological diagnosis of non-small cell lung cancer (NSCLC) stage IIIB-IV * Initiation of first-line treatment for advanced NSCLC with any platinum-based doublet chemotherapy, with or without additional targeted agents * 18 years of age or older Exclusion Criteria: * Participating simultaneously in a study including administration of any investigational drug or procedure at entry into this study
References
Publications (1)
- DERIVEDSchnabel PA, Smit E, Carpeno Jde C, Lesniewski-Kmak K, Aerts J, Kraaij K, Visseren-Grul C, Dyachkova Y, Taipale K, Girvan A, Moro-Sibilot D. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME). Lung Cancer. 2012 Dec;78(3):263-9. doi: 10.1016/j.lungcan.2012.09.001. Epub 2012 Oct 4. PMID 23040326